Linked Life Data

11283917

Source:http://linkedlifedata.com/resource/pubmed/id/11283917

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2001-4-3
pubmed:abstractText
This study evaluated the dose-response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5-minute infusion in patients with malignant osteolytic disease.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0008-543X
pubmed:author
pubmed:copyrightInfo
Copyright 2001 American Cancer Society.
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1191-200
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11283917-Antineoplastic Agents, pubmed-meshheading:11283917-Bone Density, pubmed-meshheading:11283917-Bone Neoplasms, pubmed-meshheading:11283917-Bone Resorption, pubmed-meshheading:11283917-Breast Neoplasms, pubmed-meshheading:11283917-Collagen, pubmed-meshheading:11283917-Collagen Type I, pubmed-meshheading:11283917-Creatinine, pubmed-meshheading:11283917-Diphosphonates, pubmed-meshheading:11283917-Dose-Response Relationship, Drug, pubmed-meshheading:11283917-Double-Blind Method, pubmed-meshheading:11283917-Female, pubmed-meshheading:11283917-Humans, pubmed-meshheading:11283917-Imidazoles, pubmed-meshheading:11283917-Infusions, Intravenous, pubmed-meshheading:11283917-Male, pubmed-meshheading:11283917-Middle Aged, pubmed-meshheading:11283917-Multiple Myeloma, pubmed-meshheading:11283917-Pain Measurement, pubmed-meshheading:11283917-Peptides, pubmed-meshheading:11283917-Tumor Markers, Biological
pubmed:year
2001
pubmed:articleTitle
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
pubmed:affiliation
Cedars-Sinai Medical Center, Los Angeles, California, USA. berensonj@cshs.org
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study